Embecta

Embecta Operating Cash Flow

The Operating Cash Flow of Embecta (EMBC) as of Nov 11, 2026 is 191.70 M USD. In the previous year, Operating Cash Flow was 35.70 M USD — a change of 436.97% (higher).

Operating Cash Flow

191.70 MUSD

YoY

436.97%

Last updated:

Operating Cash Flow of Embecta is 2025 191.70 M USD. Operating Cash Flow of Embecta was 2024 35.70 M USD. It decreases by 436.97% higher compared to the previous year.

The Embecta Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2019
505.00 M USD
Jan 1, 2020
498.50 M USD
Jan 1, 2021
456.00 M USD
Jan 1, 2022
412.20 M USD
Jan 1, 2023
67.70 M USD
Jan 1, 2024
35.70 M USD
Jan 1, 2025
191.70 M USD
The Embecta Operating Cash Flow history
YEAROperating Cash FlowYoY
191.70 MUSD+436.97%
35.70 MUSD-47.27%
67.70 MUSD-83.58%
412.20 MUSD-9.61%
456.00 MUSD-8.53%
498.50 MUSD-1.29%
505.00 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Embecta Stock analysis

What does Embecta do? Embecta Corp. generates revenue through the manufacturing and distribution of medical devices for diabetes treatment, including pen needles, syringes, and safety injection devices. Its product portfolio features sterile, single-use pen needles designed for use with insulin pens, safety pen needles with dual-end shields to prevent needlestick injuries, and sterile insulin syringes for drawing insulin from vials. The company sells these products through retail, hospital, pharmacy, and institutional channels to customers managing diabetes. The firm’s digital application, integrated with its physical products, supports diabetes management by assisting users in tracking and administering insulin. This complementary digital solution enhances the value of its device offerings, attracting both individual consumers and healthcare institutions seeking comprehensive diabetes care solutions. Embecta Corp. focuses on providing end-to-end solutions for people living with diabetes, leveraging its product range and digital tools to address key challenges in diabetes management. Embecta is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Embecta stock

Operating Cash Flow of Embecta is 191.70 M USD in 2025.

Operating Cash Flow of Embecta changed from 35.70 M USD to 191.70 M USD, representing a 436.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Embecta since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Embecta historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Embecta

All Key Metrics — Embecta